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Recent genome-wide association studies (GWAS)
have revealed strong association of hypercholester-
olemia and myocardial infarction with SNPs on
human chromosome 1p13.3. This locus covers three
genes: SORT1, CELSR2, and PSRC1. We demon-
strate that sortilin, encoded by SORT1, is an intracel-
lular sorting receptor for apolipoprotein (apo) B100. It
interacts with apoB100 in the Golgi and facilitates the
formation and hepatic export of apoB100-containing
lipoproteins, thereby regulating plasma low-density
lipoprotein (LDL) cholesterol. Absence of sortilin in
gene-targeted mice reduces secretion of lipopro-
teins from the liver and ameliorates hypercholester-
olemia and atherosclerotic lesion formation in LDL
receptor-deficient animals. In contrast, sortilin over-
expression stimulates hepatic release of lipoproteins
and increases plasma LDL levels. Our data have
uncovered a regulatory pathway in hepatic lipopro-
tein export and suggest a molecular explanation for
the cardiovascular risk being associatedwith 1p13.3.
INTRODUCTION
Elevated levels of LDL are key contributors to atherosclerosis
and ischemic heart disease, the leading cause of morbidity
and mortality worldwide. The high heritability of circulating LDL
levels is well established, and earlier studies of individuals with
extreme lipid values or families with Mendelian forms of dyslipi-
demias have identified key genes involved in control of LDL
metabolism (Havel and Kane, 2001).
LDL is mainly generated by lipolysis in the circulation from
liver-derived very low-density lipoproteins (VLDLs) that contain
apoB100 as a main structural component. Genetic variants of
apoB100, causing low VLDL secretion, are associated with
reduced plasma LDL (Hooper et al., 2005). Similarly, mutationsCell Mein apoB or the microsomal triglyceride carrier protein (MTP)
essential for lipidation of apoB in hepatocytes result in impaired
release of VLDL particles from the liver and in reduced plasma
LDL cholesterol levels (Sharp et al., 1993; Young et al., 1990).
In contrast to defects in hepatic release of lipoproteins, mono-
genic diseases that affect clearance of circulating LDL particles
as in familial hypercholesterolemia, an inheritable defect in the
LDL receptor gene, result in massive increase in circulating
LDL levels and in elevated risk of cardiovascular disease
(Goldstein et al., 2010).
While rare monogenic diseases have been instrumental in
establishing main concepts of hepatic lipoprotein metabolism,
many more genes may be involved in modulation of lipid homeo-
stasis and in conferring risk for CAD in the general population.
While the contribution of individual risk genes may be modest
compared with major familial disease genes, the compound
action of these modifiers is likely to play a decisive role in the
complex genetic of CAD. To identify novel modifiers and risk
factors in lipid metabolism, a number of genome-wide associa-
tion studies (GWAS) have been carried out aiming to identify
new gene loci associated with plasma LDL and cholesterol levels
or with myocardial infarction.
Remarkably, GWAS replicated in several populations have
identified three common single-nucleotide polymorphisms
(SNPs) on 1p13.3 strongly associated with reduced plasma
LDL and coronary heart disease (Linsel-Nitschke et al., 2009;
Kathiresan et al., 2008, 2009; Willer et al., 2008; Samani et al.,
2007, 2008, 2009; Sandhu et al., 2008; Karvanen et al., 2009;
Muendlein et al., 2009; Schadt et al., 2008). These SNPs lie in
a noncoding region in the vicinity of CELSR2, PSRC1, and
SORT1 that encodes cadherin EGF LAG seven-pass G-type
receptor 2, proline/serine-rich coiled-coil 1, and sortilin, respec-
tively. Which of the three genes may represent the cardiovas-
cular risk gene is unclear.
Sortilin is one of five members of the Vps10p domain receptor
family, a group of multifunctional proteins typically found in intra-
cellular compartments of the trans-Golgi network (TGN) and early
endosomes (Willnow et al., 2008). The unifying structural motif in
this gene family is the Vps10p domain, a ten-bladed b-propeller
fold that composes part of the extracellular domain of alltabolism 12, 213–223, September 8, 2010 ª2010 Elsevier Inc. 213
Figure 1. Lipoprotein Metabolism in Wild-
Type and Sortilin-Deficient Mice
(A and B) (A) Plasma cholesterol and (B) triglyc-
eride levels in mice fed a Western-type diet for
6 weeks (Sort1+/+, n = 46;Sort1/, n = 15; Ldlr/,
n = 26; Sort1/ 3 Ldlr/ mice, n = 18).
(C) Western blot analysis of apoB100, apoB48,
and apoE in plasma samples frommice of the indi-
cated genotypes.
(D) FPLC profiles of plasma samples from Sort1+/+
(n = 3), Sort1/ (n = 6), Ldlr/ (n = 4), and
Sort1/ 3 Ldlr/ (n = 5) mice. Cholesterol
concentrations (mM) in VLDL, IDL, LDL, and HDL
fractions, respectively, are shown below.
(E) Atherosclerotic lesions (arrowheads) in the
aorta of Ldlr/ but not of Sort1/ 3 Ldlr/
mice fed a Western-type diet for 8 months as
shown by bright-field microscopy (left panel) or
oil red O (right pane). Representative examples
from a total of six animals in each group are
shown.
(F) Percent plaque area in the aortas of the mice of
the indicated genotypes (n = 6 per group). All
values are depicted as mean ± SEM.
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as inactive precursor that is incapable of ligand binding due to
a 40 amino acid propeptide that precludes ligands from entering
the binding site inside a tunnel formed by the tertiary structure of
the b-propeller (Munck et al., 1999;Quistgaard et al., 2009). In the
TGN, proconvertases liberate the propeptide conferring activity
to the receptor (Munck et al., 1999).
Amongother functions, Vps10pdomain receptors are believed
to assist in sorting of target proteins in the secretory and/or
the endosomal pathways. Yet sortilin has also been recognized
as a crucial component of the signaling complex whereby214 Cell Metabolism 12, 213–223, September 8, 2010 ª2010 Elsevier Inc.proneurotrophins control survival of
neurons (Jansen et al., 2007; Nykjaer
et al., 2004). Although sortilin has been
shown to bind apoA-V (Nilsson et al.,
2008) and lipoprotein lipase (Nielsen
et al., 1999), a potential contribution of
this receptor to lipoprotein metabolism
remains enigmatic.
The present study aimed at exploring
the relevance of sortilin as a cardiovas-
cular risk factor.
RESULTS
Loss ofSortilin ExpressionProtects
from Hypercholesterolemia
Mice deficient in sortilin (Sort1/) fed
a Western-type diet exhibit a significant
20% reduction in plasma cholesterol
(2.5 ± 0.3 versus 2.0 ± 0.2 mmol/L) but
not triglyceride levels compared with
wild-type controls (Figures 1A and 1B).
When crossed with the LDL receptor-
deficient line (Ldlr/) to increase plasma
LDL levels, absence of sortilin diminished plasma cholesterol
from 11.9 ± 0.8 in Ldlr/ to 8.4 ± 0.5 mmol/L in (Sort1/ 3
Ldlr/) double knockout (DKO) mice, corresponding to an
30% decline. Triglycerides were reduced from 1.3 ± 0.1 to
0.8 ± 0.1 mmol/L (Figures 1A and 1B). Using western blot
analysis, we noticed a decrease in plasma levels of apoB100,
but not of apoB48, in DKO animals (Figure 1C). Densitometric
scanning of replicate western blot experiments revealed
a 48.2% ± 3.19% decrease in apoB100 in the DKOs (n = 7)
compared with Ldlr/mice (n = 6) (p = 0.001). This observation
was substantiated by FPLC analysis, which revealed that
Figure 2. Lipoprotein Metabolism in Mice
following Adenovirus-Mediated Hepatic
Overexpression of Sortilin
(A) Western blot analysis of sortilin and lacZ
expression in liver samples of mice treated with
adenoviruses encoding sortilin (Av-sortilin) or
b-galactosidase (Av-lacZ).
(B) Plasma cholesterol levels in Av-sortilin (n = 6)-
and Av-lacZ (n = 5)-treated mice fed a Western-
type diet.
(C) Immunoblot analysis of apoB100, apoB48, and
apoE in plasma samples from virus-infected
animals as indicated.
(D) Quantification of intensities of the immunore-
active bands in the western blot in (C). Data are
normalized to the intensity of apoB100 in
Av-lacZ-treated mice (set at 1).
(E) Mean FPLC profiles of three samples from both
virus-treated groups at day 14 postinfection. All
values are depicted as mean ± SEM.
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significantly reduced in DKO mice (Figure 1D). In line with
reduced plasma cholesterol, we also observed a considerable
reduction in the extent of atherosclerotic lesions in the aortas
of Sort1/ 3 Ldlr/ compared with Ldlr/ mice as shown by
bright-field microscopy of whole-mount aortas and by Oil Red
O staining (Figure 1E). Quantification of six animals per group
demonstrated a reduction in the percentage of plaque area
from 33.68% ± 7.18% in the LDLR-deficient mice to 13.77% ±
2.86% in the Sort1/ 3 Ldlr/ animals, corresponding to an
overall 59% (p = 0.018) decrease in atherosclerotic lesion
formation (Figure 1F).
Overexpression of Sortilin Increases Plasma
Cholesterol
Outside the nervous system, sortilin is expressed in adipose
tissue and in liver, tissues that both contribute to systemic lipo-
protein metabolism (see Figure S1A available online). In both
human and mouse livers, sortilin expression was confined to
hepatocytes (Figures S1B and S1C). To test whether hepatic
dysfunction may account for the LDL phenotype seen in sorti-
lin-deficient animals, we overexpressed the receptor selectively
in hepatocytes in vivo by adenoviral gene transfer. We reasoned
that enhanced expression, as opposed to loss of activity in
sortilin knockout mice, should increase plasma LDL.
To this end, recombinant adenoviruses encoding sortilin
(Av-sortilin) or b-galactosidase (Av-lacZ) were injected into the
tail veins of wild-type mice. Seven days later, robust overexpres-
sion of the transgenes in the livers of mice was seen (Figure 2A).
When comparing plasma cholesterol levels between the groups,
Av-sortilin-injected animals showed an 42% increase in total
cholesterol (p = 0.001; Figure 2B). Hypercholesterolemia sus-
tained for the time period observed here (14 days). In contrast,
plasma cholesterol levels in Av-lacZ-treated mice remained
unchanged compared to that of noninjected controlsCell Me(Figure 2B). Likewise, Av-sortilin application in DKO animals
reverted the LDL cholesterol-lowering effect of the sortilin
gene defect and resulted in a hypercholesterolemic phenotype
in DKO (from 8.70 ± 0.48 mM to 11.56 ± 0.11 mM; p = 0.04)
comparable to that of the Ldlr/ line (11.87 ± 0.73 mM)
(Figure S2A). The increase in plasma cholesterol in Av-sortilin-in-
jected animals was accompanied by a rise in plasma apoB100
(44%), but not apoB48 content, suggesting that sortilin selec-
tively impacts on apoB100 bioavailability (Figures 2C and 2D).
FPLC analysis confirmed accumulation of LDL/IDL particles in
the circulation of Av-sortilin- compared with Av-lacZ-treated
mice (Figure 2E). HDL was only marginally affected. Plasma
apoE levels were also increased in mice overexpressing sortilin
(Figure 2D). This finding is in line with the fact that hepatic
apoE secretion is positively correlated with VLDL production,
as the apolipoprotein is associated with these liver-derived
triglyceride-rich particles.
To demonstrate that the reduced hepatic lipoprotein export in
Sort/ mice was not accounted for by secondary changes in
gene expression or hepatic morphology, we analyzed liver
samples by gene arrays and by histology. In the transcriptome
analysis, of 84 key genes in hepatic lipoprotein and cholesterol
metabolism tested here (Figures S2B and S2C), only two tran-
scripts were changed by more than 3-fold in sortilin-deficient
mice: transcriptional regulating factor 1 (Trerf1/TReP-132),
a regulator of the steroidogenic pathway but with unknown func-
tions in the liver (Guo et al., 2007), was reduced 6.48-fold. The
second gene encoded cholesterol 7a-hydroxylase (CYP7A1),
an enzyme that catalyzes the first reaction in the cholesterol cata-
bolic pathway in the liver converting cholesterol into bile acids
(Norlin and Wikvall, 2007). A 3.43-fold increase in CYP7A1
expression was confirmed by quantitative RT-PCR (Figure S2D)
and western blotting (inset to Figure S2D), suggesting that
hepatic lipid accumulation might be affected by sortilin defi-
ciency. To exclude a confounding influence from LDLtabolism 12, 213–223, September 8, 2010 ª2010 Elsevier Inc. 215
Figure 3. Binding of apoB100 to Sortilin
(A) Immunofluorescence detection of endogenous sortilin and apoB100 in
HepG2 cells. Sortilin (red) and apoB100 (green) colocalize in a mannosidase
II-positive (blue, middle panel), but not in a calnexin-positive (blue, upper
panel), cellular compartment. Sortilin (red) interacts with apoB100 (green) in
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216 Cell Metabolism 12, 213–223, September 8, 2010 ª2010 Elsevieendocytosis, we compared the lipid content in livers from Ldlr/
and Sort1/ 3 Ldlr/ mice. Despite indistinguishable
morphology of livers from the two genotypes, Sudan staining
uncovered a reduction in hepatic lipid accumulation in the
DKOs (FigureS2E). In accordance, biochemical quantification re-
vealed a decrease in hepatic triglycerides from 159.09 ± 29.16 to
83.22 ± 10.80 mg/mg tissue, corresponding to an 48%
reduction in the DKO animals (p = 0.04). Cholesterol levels
were unchanged in these mice (3.84 ± 0.22 versus 3.81 ±
0.18 mg/mg). This observation suggests that increased Cyp7a1
expression may enhance biliary excretion shunt from the liver of
receptor-deficient mice.
Expression of the remaining 82 genes was unaffected. Most
importantly, Apob transcript levels were unaltered (Figure S2B).
Also, transcript levels for Psrc1 and Celsr2, the other two
candidate genes at 1p13.3, were unchanged in sortilin-deficient
mice as shown by quantitative RT-PCR (Figure S2F).Sortilin Functionally Interacts with apoB100
but Not apoB48
Based on a function for Vps10p domain receptors as intracellular
sorting proteins, we hypothesized that sortilin may interact with
apoB100 and facilitate hepatic VLDL biosynthesis and release.
To explore this possibility, we first studied if endogenous sortilin
and apoB100 colocalize in the human hepatoma cell line HepG2
using immunofluorescence microscopy (Figure 3A and Figures
S3A and S3B). We found that apoB100 is predominantly present
in the endoplasmic reticulum (ER) (calnexin-positive), in line with
previous reports (Boren et al., 1990; Sakata et al., 2001), but also
in medial- to trans-Golgi compartments (mannosidase II posi-
tive). Interestingly, sortilin colocalized with apoB100 selectively
in the Golgi. By fluorescence resonance energy transfer (FRET)
and after subtraction of the signals from donor only and acceptor
only to correct for spectral bleach through, we calculated an
average pFRET of 10% ± 4% (Figure 3A and Figure S3C), indi-
cating a high degree of apoB100 binding to sortilin in this secre-
tory compartment. To further substantiate the ability of apoB and
sortilin to physically interact, we performed coimmunoprecipita-
tion of endogenous sortilin with anti-apoB antisera from
hepatoma cells. In these studies, a distinct fraction of sortilin co-
precipitated with apoB, in line with a transient interaction of the
two proteins in the TGN (Figure 3B). Coimmunoprecipitation ofthe perinuclear region as demonstrated by pFRET efficiency (lower panel).
Nuclei are indicated by dotted circles.
(B) (Left) Coimmunoprecipitation of endogenous sortilin with anti-apoB IgG
(IP ApoB, lane 2), but not with control IgG (IP IgG, lane 4) from HepG2 cells.
IP designates the immunoprecipitate (lanes 2 and 4) and SN the corresponding
supernatant of the IP reaction (lanes 1 and 3). Samples were probed for sortilin
(upper panel) and apoB100 (lower panel) (B, right). Coimmunoprecipitation of
endogenous apoB from human liver with anti-sortilin IgG (lane 3) but not with
nonimmune control IgG (lane 2). As a positive control, immunoprecipitation of
apoB100 with anti-apoB antisera is shown in lane 1.
(C) SPR analysis showing binding of the indicated concentrations of mouse
VLDL but not of human chylomicrons (CM) to the immobilized sortilin ectodo-
main (0.108 fmol/mm2).
(D) BIAcore analysis of a concentration series of human LDL showing binding
to the immobilized ectodomain of mature sortilin but not to cleavage-resistant
prosortilin (0.096 fmol/mm2). The calculated affinity (Kd) for sortilin is 1–2 nM.
r Inc.
Figure 4. Sortilin Expression Modulates Subcellular Distribution
of apoB100 in Mouse Hepatocytes
(A) Immunofluorescence detection of apoB (green) and sortilin (red) in primary
hepatocytes from Sort+/+ wild-type mice or from Sort/ animals treated with
lacZ (Av-lacZ) or sortilin-expressing (Av-sortilin) adenoviruses. Sortilin overex-
pression relocates apoB from an ER-like to a Golgi-like compartment in
Sort/ cells (arrowheads), similar to the pattern seen for apoB100 in Sort+/+
cells. Of note, the anti-sortilin antisera applied does recognize the human
receptor expressed from the viral gene construct, but not the endogenous
murine protein in noninfected wild-type cells (upper panel).
(B) Subcellular fractionation of hepatic microsomal membranes. In wild-type
mice, apoB100 and apoB48 colocalize with sortilin in Golgi-enriched fractions
positive for TGN46 (fractions 12–16). In sortilin-deficient mice, apoB100 is
shifted to lighter fractions corresponding to the calnexin-positive ER (fractions
2–8).
(C and D) (C) Relative distribution of apoB100 and (D) apoB48 in subcellular
fractions from four independent experiments as determined by densitometric
scanning of western blots exemplified in (B). Values (mean ± SEM) are normal-
ized to the total expression of apoB100 and apoB48 in wild-typemice, respec-
tively.
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Cell Meboth proteins was also documented from human liver specimens
(Figure 3B).
Next, we tested which apoB isoform, apoB100 or apoB48,
was capable of sortilin binding. To do so, the extracellular
domain of sortilin was immobilized on a sensor chip and VLDL
binding to the protein domain was characterized by surface
plasmon resonance (SPR) analysis. To exclude potential binding
through apoE, we used VLDL particles purified from apoE-defi-
cient mice. As shown in Figure 3C, purified VLDL particles
exhibited a robust binding to sortilin. Because VLDL contains
both apoB100 and apoB48, we also tested binding of human
chylomicrons (CMs) that contain apoB48 and apoE as well as
that of LDL particles that carry apoB100 only.While we observed
strong interaction of the sortilin ectodomain with LDL (Figure 3D;
Kd 1–2 nM), CM were completely inactive (Figure 3C). The
specificity of VLDL and LDL interaction with sortilin was further
evidenced using competition experiments with neurotensin
and the receptor-associated protein (RAP), potent inhibitors of
ligand binding to sortilin (Nielsen et al., 1999). Neurotensin
(20 mM) inhibited VLDL (125 mg/ml) and LDL (60 nM) binding
by 33% and 42%, respectively. RAP (5 mM) completely abol-
ished interaction between LDL and sortilin98%.We concluded
that apoB100, but not apoB48, is capable of binding to sortilin
with high affinity, an interaction which likely proceeds in late
Golgi compartments.Sortilin Modulates Intracellular Trafficking
and Release of apoB100
To gain further insights into the molecular mechanism by which
sortilin affects plasma LDL, we overexpressed lacZ or sortilin
by adenoviral gene transfer in Sort1/ hepatocytes
(Figure 4A). While in wild-type cells apoB was mainly present in
a perinuclear Golgi-like compartment, hepatocytes lacking
sortilin and transfected with Av-lacZ showed a dispersed apoB
staining throughout the cell, consistent with a predominant ER
localization. In contrast, re-expression of sortilin (Av-sortilin) in
Sort1/ hepatocytes resulted in a robust accumulation of
apoB100 in a Golgi-like perinuclear compartment that also con-
tained sortilin (Figure 4A and Figure S4). This observationtabolism 12, 213–223, September 8, 2010 ª2010 Elsevier Inc. 217
Figure 5. Sortilin Regulates apoB100 Secretion, but Not Degrada-
tion, in Primary Hepatocytes
(A) Immunoprecipitation of apoB100 and apoB48 from themediumofmetabol-
ically labeled primary hepatocytes of the indicated genotypes. Albumin was
immunodetected as internal reference for metabolic labeling and secretion
efficiency.
(B and C) (B) Quantification of data sets for apoB100 and (C) apoB48 as exem-
plified in (A) (n = 4 for each genotype). Intensities (mean ± SEM) are given rela-
tive to the total amount of apoB100 and apoB48, respectively, in wild-type
samples (set at 1).
(D) Immunoblots for apoB100 and apoB48 in wild-type hepatocytes infected
with Av-sortilin or Av-lacZ (left) and quantification thereof (right). Values are
mean ± SEM.
(E) ApoB100 and apoB48 in wild-type and Sort1/ mouse hepatocytes.
Where indicated, replicate cell cultures were incubated with sortilin-express-
ing adenovirus (Av-sortilin) and with the lysosomal inhibitors leupeptin and
pepstatin A.
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apoB100, thereby affecting its subcellular localization.
Aswell as in cultured cells, we also characterized the impact of
sortilin deficiency on intracellular trafficking of apoB100 in vivo.
We subjected microsomal membranes from livers of wild-type
and sortilin-deficient mice to subcellular fractionation and deter-
mined the distribution of apoB100, apoB48, apoE, and sortilin by
immunoblotting. In wild-type mice, apoB100 and apoB48 were
present in ER but also in Golgi-enriched fractions where they co-
localized with sortilin (fractions 12–16; Figure 4B). Disruption of
Sort1 shifted the distribution of apoB100 toward ER fractions
(fractions 2–6), suggesting that sortilin is required for efficient
transit of apoB100 through the biosynthetic pathway (Figures
4B and 4C; p < 0.0003). In the absence of sortilin, there was
also a tendency for buildup of apoB48 in the ER, but this effect
was not significant (Figures 4B and 4D; p = 0.15). Sortilin defi-
ciency did not affect subcellular localization of apoE (Figure 4B).
Calculating the total amount of apoB100 present in the subcel-
lular fractions revealed a 57% increase in apolipoprotein content
in the livers of sortilin/ compared with sortilin+/+ mice, albeit at
normal Apob transcript levels (Figure S2B). Metabolic labeling of
primary hepatocytes substantiated faulty release of apoB100
from sortilin-deficient cells. Thus, after an extended chase
period, 54% less apoB100 molecules were secreted into the
medium of Sort1/ hepatocytes compared with control cells
(Figures 5A and 5B). Excretion of apoB48, on the other hand,
was not affected (Figures 5A and 5C). In support of sortilin-medi-
ated apoB100 secretion, adenoviral-mediated overexpression of
sortilin, but not of lacZ, in wild-type hepatocytes was accompa-
nied by an54% reduction in cellular apoB100 (but not apoB48)
as shown by western blotting (Figure 5D). Likewise, apoB100
accumulation was notably diminished following sortilin overex-
pression in both wild-type and in Sort1/ hepatocytes (Fig-
ure 5E).
Sortilin has been proposed to mediate TGN to endosome/
lysosome sorting of target proteins. To exclude any confounding
effects from lysosomal sorting on the cellular apoB100 concen-
tration, we also treated sortilin overexpressing hepatocytes with
lysosomal enzyme inhibitors leupeptin and pepstatin A. When
comparing the cellular apoB100 content with and without treat-
ment, we failed to see an obvious accumulation of the apoprotein
in the presence of lysosomal inhibitors, suggesting that sortilin isr Inc.
Figure 6. Sortilin Facilitates Hepatic Lipoprotein Export via Binding
of apoB100 in the trans-Golgi Network
(A) Mice of the indicated genotypes were treated with tyloxapol, and plasma
sampleswere collected at the indicated time points and analyzed for triglyceride
concentrations (n = 5 animals per group). Triglycerides values are mean ± SEM.
(B) Western blot analysis of apoB100, apoB48, and apoE in representative
plasma samples from the experiment shown in (A).
(C) Genotyping of livers from mice treated with Av-sortilin and Av-prosortilin.
Introduction of a point mutation in prosortilin disrupts a BsaHI restriction site in
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Cell Meunlikely to mediate endosome/lysosome sorting of apoB100
(Figure 5E).Sortilin Promotes Hepatic Export
of apoB100-Containing Lipoproteins In Vivo
In a recent study, recombinant overexpression of sortilin in
human embryonic kidney 293 cells resulted in amodest increase
in cellular uptake of LDL (Linsel-Nitschke et al., 2009). Thus,
a potential role for this receptor in promoting clearance of LDL
was proposed. This hypothesis contrasts with our data from sor-
tilin-deficient mice that exhibit reduced levels of LDL compared
to mice expressing the receptor (Figure 1D). To test an effect of
endogenous sortilin on hepatic LDL uptake, we measured LDL
receptor expression and endocytic uptake of purified LDL in
primary hepatocytes from wild-type and sortilin-deficient
animals. No difference in LDL receptor expression (Figure S2B)
or LDL uptake (Figure S5) was seen comparing genotypes.
Taken together, our cellular studies suggested that sortilin
binds apoB100 in the distal secretory pathway and regulates
its sorting and/or incorporation into nascent lipoprotein particles,
thereby facilitating their release from cells. To confirm that this
model also applies to the in vivo situation, we injected wild-
type and Sort1/ mice on a Western-type diet intravenously
with tyloxapol (Triton WR-1339), an inhibitor of lipolysis that
prevents breakdown of VLDL to LDL. Two hours after tyloxapol
application, triglyceride levels (indicative of newly secreted
VLDL particles) were 22% lower in Sort1/ compared with
wild-type animals (Figure 6A, p = 0.006). Total cholesterol levels
were unchanged, in accordance with fatty acids being a major
component of VLDL particles (Figure S6A). In wild-type animals,
the levels of apoB100 remained fairly constant following
tyloxapol treatment, likely reflecting that VLDL production is
balanced by a simultaneous clearance of pre-existing LDL parti-
cles during the 2 hr time course of the experiment (Figure 6B).
In contrast, there was noticeably less apoB100 in the plasma
of sortilin-deficient mice. ApoB48 and apoE accumulated in
the plasma of tyloxapol-treated animals regardless of the geno-
type (Figure 6B).
Lastly, we further elucidated the cellular mechanism whereby
sortilin may control biogenesis and hepatic release of VLDL. We
took advantage of a sortilin mutant, denoted prosortilin, that
harbors mutations in the amino acid sequence required for
proteolytic cleavage of the receptor propeptide. Because the
propeptide blocks entry of ligands to the binding pocket, the
activity of sortilin is conditioned on the release of the propeptide
from the receptor by proconvertases in the TGN (Munck et al.,
1999). Using SPR analysis we showed that LDL was not able
to bind to prosortilin (Figure 3D). Moreover, addition of 5 mM
recombinant propeptide inhibited binding of VLDL (125 mg/ml)
to mature sortilin by 85%. These findings suggested that the
interaction between apoB100 and sortilin likely occurs in a distala RT-PCR product (upper panel). Virus expression is confirmed bywestern blot-
ting (lower panel).
(D) Plasma cholesterol levels in mice fed a Western-type diet and infected with
Av-sortilin (n= 6), Av-prosortilin (n = 6), or Av-lacZ (n = 6) for the indicatedperiods
of time.Cholesterol valuesaremean±SEM relative toplasma levelsprior to virus
treatment.
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Figure 7. Model of Sortilin Action in Hepatic
Lipoprotein Export
(A) Model of VLDL production in the secretory
pathway of hepatocytes involving the activity of
MTP in the ER and sorting receptor sortilin in the
TGN.
(B) Impaired formation and release of VLDL1 in
sortilin-deficient hepatocytes result in blockade
of apoB100 export form the ER.
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To substantiate the physiological relevance of this finding, we
overexpressed prosortilin by adenoviral-mediated gene transfer
(Av-prosortilin) in mice and compared the effects to those
elicited by overexpression of the wild-type receptor (Av-sortilin).
Infection of mice in both groups (Figure 6C, upper panel) resulted
in similar levels of hepatic overexpression of the two receptor
variants (Figure 6C, lower panel). Yet prosortilin was unable to
increase cholesterol levels in the animals as opposed to the
mature wild-type receptor, which went up by 70% at day 7
(Figure 6D). Similarly to Av-prosortilin, treatment with Av-lacZ
control virus preparations did not affect systemic cholesterol
levels (Figure 6D). In agreement with increased sortilin-mediated
VLDL release, total triglycerides were increased by 138%
(Figure S6B). Thus, we concluded that sortilin mediates its effect
on lipoprotein export in the TGN by direct interaction with
apoB100.
DISCUSSION
Previous studies identified SNPs at 1p13.3 strongly associated
with plasma LDL and risk of CAD. This locus covers the genes
SORT1, PSRC1, and CELSR2. Using transgenic mouse models
that either overexpress or lack sortilin, we identified sortilin as
a regulator of hepatic lipoprotein production and plasma LDL
cholesterol. According to our model, the receptor facilitates traf-
ficking and assembly of VLDL in the distal Golgi compartment of
liver cells where formation of triglyceride-rich particles from lipi-
dated apoB100 proceeds (reviewed in Olofsson et al., 2007).
In wild-type hepatocytes, formation of VLDL particles starts
with lipidation of nascent apoB100 polypeptide chains that are
being translocated into the lumen of the ER (Figure 7A). Lipida-
tion of the apolipoprotein involves the activity of MTP
(Figure 7A, step 1). Primordial particles (pre-VLDL) are further
lipidated to form a triglyceride-poor form of VLDL (VLDL2; Fig-
ure 7A, step 2) that reaches the Golgi, where it is converted
into triglyceride-rich VLDL1 by addition of triglycerides from lipid
droplets (Figure 7A, step 4). We propose that assembly and
release of VLDL1 (steps 4 and 5) may require interaction of
apoB100 with mature sortilin that becomes proteolytically acti-
vated in the distal Golgi (step 3). The presence of the propeptide
in prosortilin prevents premature association of the receptor with220 Cell Metabolism 12, 213–223, September 8, 2010 ª2010 Elsevier Inc.nascent apoB100 chains in the ER.
Based on our findings, loss of sortilin
activity likely impairs formation and re-
lease of VLDL1 in the Golgi (Figure 7B,
step 6), and thereby impedes vesicular
transport of apoB100 through the sec-retory pathway. This block results in backlog of apoB100 traf-
ficking and impaired release of pre-VLDL from the ER
(Figure 7B, step 7).
Many phenotypes seen in sortilin-deficient mice are also
observed in conditions of hypo- and abetalipoproteinemia,
supporting a role for the receptor in promotion of VLDL produc-
tion. For example, genetic ablation or pharmacological blockade
ofMTP reduces hepatic secretion of apoB100, but onlymodestly
apoB48, and, consequently, impairs VLDL export from the liver
(Chang et al., 1999; Liao et al., 2003; Raabe et al., 1999). The
same phenotype is seen when inactivating Sort1. Enhanced
production and release of apoB100-containing lipoproteins are
also seen when overexpressing wild-type sortilin (Figures 2
and 6D). As opposed to models of hypobetalipoproteinemia,
sortilin-deficient hepatocytes do not accumulate cholesterol in
the liver. One possible explanation is the apparent increase in
expression of CYP7A1, presumably resulting in enhanced biliary
excretion of the sterol. The effect of sortilin on hepatic lipoprotein
metabolism in vivo is critically dependent on the ability of the
receptor to interact with ligands, as prosortilin that is devoid in
apoB100 binding fails to modulate plasma cholesterol levels
(Figure 6D).
Mechanistically, hypo- and abetalipoproteinemia caused by
apoB and MTP gene defects, respectively, are associated with
a dysfunction in the ER (Chang et al., 1999; Du et al., 1994;
Raabe et al., 1999). In contrast, sortilin deficiency seems to
impair lipoprotein secretion at a later stage along the secretory
pathway, likely in transit through the Golgi. A general function
for sortilin and related Vps10p domain receptors in protein
sorting at the TGN has previously been proposed based on their
structural homology to the vacuolar protein sorting 10 protein
(VPS10P), a sorting receptor in Yeast that directs carboxypepti-
dase Y to the vacuole (Marcusson et al., 1994). This hypothesis
was supported by findings in mammalian cell lines that the cyto-
plasmic tail of sortilin was able to direct chimeric mannose
6-phosphate receptors from the TGN into endosomal/lysosomal
pathways (Nielsen et al., 2001).
A proposed role for Vps10p domain receptors in sorting
processes at TGN was confirmed using gene-targeting or
knockdown approaches as discussed below. However, these
studies failed to support a function for the receptors in targeting
proteins into lysosomal degradation. Rather, the mammalian
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through the late secretory pathway to the cell surface. For
example, inactivation of SORLA, a sorting receptor for the
amyloid precursor protein (APP), resulted in enhanced shunt of
APP to the cell surface and in aggravated proteolytic processing
into amyloid b-peptides (Andersen et al., 2005; Schmidt et al.,
2007). Knockdown of sortilin expression in primary neurons
impaired regulated release of its ligand brain-derived neurotro-
phic factor (Chen et al., 2005). Also, new studies presented
here did not reveal a distinct effect of sortilin on targeting of
apoB100 to lysosomal pathways (Figures 5D and 5E). This
observation is in line with the fact that posttranscriptional regula-
tion of apoB100 biogenesis by proteolytic degradation mainly
involves autophagosomes and, to some extent, also protea-
somes and the ER (Pan et al., 2008; Hooper et al., 2005).
Levels of sortilin activity are directly correlated with plasma
LDL cholesterol concentrations in mice. Thus, loss of receptor
activity reduces plasma cholesterol levels by 20% on the wild-
type LDL receptor background and by 30% in Ldlr/ animals
(Figure 1A). As a result, development of atherosclerotic plaques
in the aorta of Ldlr/ mice is considerably impaired on the
sortilin knockout background (Figure 1E). When the activity of
the receptor is increased (as in Av-sortilin treated mice), plasma
cholesterol levels rise by up to 75% (Figures 2B and 6D). Similar
changes in plasma LDL and cholesterol have been identified in
individuals with the minor 1p13.3 allele variant. Based on epide-
miological studies, each minor allele translates into an4%–9%
reduction in plasma cholesterol, depending on the ethnic group
studied (Linsel-Nitschke et al., 2009; Willer et al., 2008; Keebler
et al., 2009; Nakayama et al., 2009). As a consequence, carriers
of the minor allele are subject to 13%–29% lower risk of CAD
(Kathiresan et al., 2009; Samani et al., 2007; Linsel-Nitschke
et al., 2009). Thus, even modest changes in LDL cholesterol
associated with altered expression of sortilin may translate into
a substantial risk burden. Of course, experiments presented in
this study do not exclude a contribution from PSRC1 and
CELSR2, also covered by the 1p13.3 locus to cardiovascular
phenotypes associated with 1p13.3. Obviously, lack of informa-
tion concerning the functional roles of these two genes in context
of the cardiovascular system impairs formulation of such hypoth-
eses. However, it is of note that levels of expression of these two
genes were unchanged in Sort1/ mice (Figure S2F).
A positive correlation of plasma cholesterol with sortilin activity
documented in mice is intriguing given the fact that a recent
study demonstrated modestly increased levels of SORT1 tran-
scripts in carriers of the minor allele variant despite reduced
plasma LDL levels (Linsel-Nitschke et al., 2009). Based on their
results, the authors argued that sortilin may act as a clearance
pathway for LDL promoting hepatic catabolism of the lipoprotein
when expression of the receptor is increased. Obviously, this
hypothesis contrasts with reduced levels of plasma LDL and
cholesterol in sortilin-deficient mice shown here. When consid-
ering this controversy, one has to keep in mind that the exact
mechanism of how SNPs associated with SORT1 affect receptor
activity is unclear at present. Any interpretation is complicated
by the fact that no functional SNPs have been identified in the
SORT1 coding region and that no information on the amount of
receptor protein or activity in the human liver is available for
SNPs identified so far. Although it is intuitive that protein concen-Cell Metration may correlate with mRNA level, this statement is only true
globally. For individual genes, the correlation of transcript and
protein level is weak, as shown in multiple genome studies
(Greenbaum et al., 2001; Ideker et al., 2001). Furthermore,
SORT1, PSRC1, andCELSR2 are all in the same linkage disequi-
librium block, and the minor allele variant also regulates expres-
sion of PSRC1 and CELSR2, genes that could exhibit opposing
functions to that of sortilin. Indeed, using quantitative trait
mapping in mouse intercrosses, Schadt et al. identified that
low expression of PSRC1 correlates with low LDL cholesterol
(Schadt et al., 2008). Thus, SORT1 mRNA levels alone may be
a poor predictor of hepatic protein activity.
Lowering LDL cholesterol is considered one of the most effi-
cient strategies to reduce the risk of CAD (Visser et al., 2008).
Identification of regulators in lipoprotein metabolism, such as
sortilin, will help to develop therapeutic strategies aimed at
reducing plasma LDL cholesterol, the single most predictive
cardiovascular risk factor.
EXPERIMENTAL PROCEDURES
Animal Experimentation
Congenic Sort1/ mice on C57BL/6J background (>98.5%) have been
described previously (Jansen et al., 2007). Ldlr/ line (C57BL/6J) was
obtained from Charles River Laboratories, Wilmington, MA. Unless stated
otherwise, experiments were carried out on mice fed a Western-type diet
(Altromin Western Diet, Brogaarden, Denmark) for 2 weeks. Permission for
animal experimentation was obtained (J. 2006/561-1206).
Lipoprotein FPLC, Cholesterol, and Triglyceride
Plasma cholesterol and triglycerides were determined in fasted animals using
the ‘‘Cholesterol CHOD-PAP’’ and ‘‘Triglycerides GPO-PAP’’ kits (Roche,
Basel, Switzerland). Measurement of lipoprotein profiles was conducted by
TNO Biosciences, Leiden, The Netherlands.
Preparation of Adenoviruses
Adenoviruses encoding human sortilin (amino acids 1–833), human prosortilin
lacking a functional furin site (RWRR to RWGG), or lacZ were propagated by
ViraQuest Inc., North Liberty, IA. Mice were injected with 2E9 pfus intrave-
nously. Hepatocytes were infected with 20 pfu/cell.
Coimmunoprecipitation
Lysed HepG2 cells (1% Nonidet P-40, 0.25% deoxycholate), incubated with
anti-apoB (ab20737, Abcam, England) or nonimmune IgG, were precipitated
using protein G agarose (Roche Applied Science, Germany).
Immunofluorescence Analysis
HepG2 cells or primary hepatocytes were fixed in 4% paraformaldehyde, per-
meabilized with 0.1% Triton X-100, blocked in 10% FCS, and incubated with
antibodies against sortilin, apoB100, mannosidase II, and/or calnexin for 24 hr
at 4C. Secondary fluorescent-labeled antibodies were used for visualization.
Pulse-Chase Experiments
Primary hepatocytes were metabolically labeled with L-[35S]cysteine and
L-[35S]methionine in the presence of Brefeldin A, washed and incubated in
complete medium, and chased for the times indicated (Munck et al., 1999).
Medium was collected, immunoprecipitated using gamma-bind Sepharose
coated with anti-albumin (A0433, Sigma Aldrich) or anti-apoB (ab20737,
Abcam), and analyzed by SDS-PAGE and fluorography.
Surface Plasmon Resonance Analysis
Sortilin and prosortilin were immobilized on a CM5 chip at 0.108 and 0.096
fmol/mm2, respectively. Sample and running buffer was 10 mM HEPES,
150 mM (NH4)2SO4, 1.5 mM CaCl2, 1 mM EGTA, 0.005% Tween-20
(pH 7.4). The SPR signal was expressed in relative response units (RUs) aftertabolism 12, 213–223, September 8, 2010 ª2010 Elsevier Inc. 221
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Sortilin Regulates Hepatic Lipoprotein Exportsubtraction of the RU in a control flow channel. Kinetic parameters were deter-
mined using BIAevaluation 3.1 software.
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